Advanced

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer

Larsson, Anna Maria LU ; Bendahl, Pär Ola LU ; Aaltonen, Kristina LU ; Jansson, Sara LU ; Forsare, Carina LU ; Bergqvist, Mattias ; Jørgensen, Charlotte Levin Tykjær LU and Rydén, Lisa LU (2020) In Scientific Reports 10.
Abstract

The rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and its activity correlates to outcome in cancer patients. The aim of this study was to evaluate serum TK1 activity (sTK1) levels in MBC patients as a tool for prognostication and treatment monitoring. 142 women with MBC scheduled for 1st line systemic treatment were included in a prospective observational study. sTK1 was measured at baseline (BL) and at 1, 3 and 6 months and correlations to progression-free and overall survival (PFS, OS) evaluated. High sTK1 levels (above median) correlated to worse PFS and OS at BL, also after adjusting... (More)

The rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and its activity correlates to outcome in cancer patients. The aim of this study was to evaluate serum TK1 activity (sTK1) levels in MBC patients as a tool for prognostication and treatment monitoring. 142 women with MBC scheduled for 1st line systemic treatment were included in a prospective observational study. sTK1 was measured at baseline (BL) and at 1, 3 and 6 months and correlations to progression-free and overall survival (PFS, OS) evaluated. High sTK1 levels (above median) correlated to worse PFS and OS at BL, also after adjusting for other prognostic factors. sTK1 levels were significantly associated with PFS and OS measured from follow-up time points during therapy. Changes from 3 to 6 months during therapy significantly correlated to PFS and OS, whereas early changes did not. We could demonstrate sTK1 level as an independent prognostic factor in patients with newly diagnosed MBC. Changes in sTK1 levels from 3 to 6 months correlated to PFS and OS. Future studies of sTK1 are warranted to further define its clinical utility.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scientific Reports
volume
10
article number
4484
publisher
Nature Publishing Group
external identifiers
  • scopus:85081730711
  • pmid:32161278
ISSN
2045-2322
DOI
10.1038/s41598-020-61416-1
language
English
LU publication?
yes
id
32c0a275-4183-434b-936a-ec5df0ce42f5
date added to LUP
2020-03-26 17:05:09
date last changed
2020-03-27 03:00:02
@article{32c0a275-4183-434b-936a-ec5df0ce42f5,
  abstract     = {<p>The rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and its activity correlates to outcome in cancer patients. The aim of this study was to evaluate serum TK1 activity (sTK1) levels in MBC patients as a tool for prognostication and treatment monitoring. 142 women with MBC scheduled for 1<sup>st</sup> line systemic treatment were included in a prospective observational study. sTK1 was measured at baseline (BL) and at 1, 3 and 6 months and correlations to progression-free and overall survival (PFS, OS) evaluated. High sTK1 levels (above median) correlated to worse PFS and OS at BL, also after adjusting for other prognostic factors. sTK1 levels were significantly associated with PFS and OS measured from follow-up time points during therapy. Changes from 3 to 6 months during therapy significantly correlated to PFS and OS, whereas early changes did not. We could demonstrate sTK1 level as an independent prognostic factor in patients with newly diagnosed MBC. Changes in sTK1 levels from 3 to 6 months correlated to PFS and OS. Future studies of sTK1 are warranted to further define its clinical utility.</p>},
  author       = {Larsson, Anna Maria and Bendahl, Pär Ola and Aaltonen, Kristina and Jansson, Sara and Forsare, Carina and Bergqvist, Mattias and Jørgensen, Charlotte Levin Tykjær and Rydén, Lisa},
  issn         = {2045-2322},
  language     = {eng},
  month        = {03},
  publisher    = {Nature Publishing Group},
  series       = {Scientific Reports},
  title        = {Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer},
  url          = {http://dx.doi.org/10.1038/s41598-020-61416-1},
  doi          = {10.1038/s41598-020-61416-1},
  volume       = {10},
  year         = {2020},
}